the potential clinical benefits of comprehensive molecular profiling in an aggressive nscl grade iv

We present a non-small cell lung cancer grade iv patient, diagnosed at 46 years of age, with multiple relapse from the diagnosis and demonstrating a poor prognosis after 3 cycles of treatments. a clinical comprehensive genomic profile was performed with the goal of finding potential actionable molecular alterations. the patient showed significant symptomatic and laboratory improvement with a combination chemotherapy determined by the molecular profiling, which would otherwise not have been considered. the mentioned approach was conducted since no other targeted therapies seemed actionable for him.